Search Result

Results for "

BTK Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Btk (202) Akt (2) Antibiotic (1) Apoptosis (19) Arp2/3 Complex (1) Autophagy (1) Bcl-2 Family (1) Bcr-Abl (1) BCRP (1) BMX Kinase (5) c-Met/HGFR (1) Calcium Channel (1) Caspase (2) CCR (1) CDK (1) CXCR (2) Cytochrome P450 (2) Dengue Virus (2) Drug Intermediate (2) Drug Isomer (1) Drug Metabolite (2) EGFR (8) Endogenous Metabolite (1) ERK (2) Fc Receptor (FcR) (1) Flavivirus (2) FLT3 (3) Fluorescent Dye (3) Fungal (1) Glutathione S-transferase (1) HMG Family (1) Interleukin Related (1) Isotope-Labeled Compounds (3) Itk (7) JAK (11) LAG-3 (2) Ligands for Target Protein for PROTAC (4) MEK (1) MNK (1) Molecular Glues (1) mTOR (1) NF-κB (2) Nuclear Factor of activated T Cells (NFAT) (1) p38 MAPK (2) Parasite (1) PARP (1) PD-1/PD-L1 (2) PERK (1) PI3K (2) Pim (1) Polo-like Kinase (PLK) (2) PROTACs (15) Pyroptosis (1) RANKL/RANK (1) Reference Standards (15) RET (1) Src (8) STAT (1) Syk (3) Target Protein Ligand-Linker Conjugates (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (1)
By Research Areas:	Cancer (155) Cardiovascular Disease (4) Endocrinology (1) Infection (6) Inflammation/Immunology (84) Metabolic Disease (5) Neurological Disease (8)
Click Chemistry:	Azide (1) Alkynes (1)

216

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Btk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10997

Ibrutinib Maximum Cited Publications 126 Publications Verification PCI-32765	Btk Ligands for Target Protein for PROTAC	Infection Inflammation/Immunology Cancer
Ibrutinib (PCI-32765) is a selective, irreversible *Btk* inhibitor with an IC₅₀ of 0.5 nM .

HY-131328

Pirtobrutinib 5 Publications Verification LOXO-305	Btk	Cancer
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation *BTK* inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM .

HY-128757

Remibrutinib 5 Publications Verification LOU064	Btk	Inflammation/Immunology Cancer
Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC₅₀ value of 1 nM. Remibrutinib inhibits BTK activity with an IC₅₀ value of 0.023 μM in blood . Remibrutinib has the potential for Chronic urticaria (CU) treatment .

HY-129390

Orelabrutinib 3 Publications Verification ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .

HY-112215

Nemtabrutinib 4 Publications Verification ARQ-531; MK-1026	Btk	Inflammation/Immunology Cancer
Nemtabrutinib (ARQ 531) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC₅₀s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

HY-11999

CGI-1746 5+ Cited Publications	Btk Autophagy	Inflammation/Immunology
CGI-1746 is a potent and highly selective inhibitor of the *Btk* with IC₅₀ of 1.9 nM.

HY-156640

Rocbrutinib LP-168	EGFR	Cancer
Rocbrutinib is an orally available, highly selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC₅₀ of 0.11 nM against wild-type *BTK* and an IC₅₀ of 1.0 nM against C481S-mutated *BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits* cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkin's lymphoma and mantle cell lymphoma .

HY-109143

Elsubrutinib 2 Publications Verification ABBV-105	Btk	Inflammation/Immunology
Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor. The IC₅₀ of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease .

HY-160167

Birelentinib DZD8586	Src Btk	Inflammation/Immunology Cancer
Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and *BTK* tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying *BTK* resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both *BTK*-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent *BTK* inhibitors in B-cell non-Hodgkin lymphoma (B-NHL) .

HY-10644

*Lck inhibitor* 2**	Src	Inflammation/Immunology
Lck inhibitor 2 is a multi-target tyrosine kinase inhibitor with IC50s of 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.

HY-13943

CNX-774 2 Publications Verification	Btk	Cancer
CNX-774 is an orally active, irreversible and selective *BTK* inhibitor, with an IC₅₀ of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification .

HY-15427

GDC-0834 1 Publications Verification	Btk	Inflammation/Immunology
GDC-0834 is a potent and selective *BTK* inhibitor. GDC-0834 inhibits BTK with an in vitro IC₅₀ of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC₅₀ of 1.1 and 5.6 μM in mouse and rat, respectively.

HY-160142

UBX-382	PROTACs Btk Syk MEK ERK	Cancer
UBX-382 is an orally active *BTK* PROTAC degrader with a DC₅₀ of 4.56 nM. UBX-382 inhibits B-cell receptor signaling by targeting BTK. UBX-382 shows superior degradation activity for wild-type and mutant *BTK* proteins. UBX-382 inhibits tumor growth in murine xenograft models harboring wild-type or C481S mutant *BTK*-expressing TMD-8 cells. UBX-382 can be used for the study of B-cell-related blood cancers .

HY-100338

CNX-500	Btk	Cancer
CNX-500 is a probe consisting of a covalent *Btk* inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against *Btk* (IC₅₀ of 0.5 nM) and the ability to form a covalent bond with *Btk*. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn .

HY-12679

PF-06658607	Btk	Cancer
PF-06658607 is an alkynylated irreversible Brutons tyrosine kinase (BTK) inhibitor that covalently reacts with active site cysteines in the ATP-binding pocket. PF-06658607 can be used to detect "off "-targets for covalent kinase inhibitors in cancer cells. The alkyne moiety allows for azide-based detection probe via copper-catalyzed click chemistry .

HY-101941

BTK IN-1 SNS062 analog	Btk	Inflammation/Immunology Cancer
BTK IN-1 (SNS062 analog) is a potent *BTK* inhibitor, with an IC₅₀ of <100 nM.

HY-163565

BIIB129	Btk	Neurological Disease
BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of *BTK* by covalently binding to Cys481 in *BTK*, thereby affecting the function of B cells and myeloid cells. BIIB129 can be used in multiple sclerosis (MS) research .

HY-132879

TAK-020	Btk	Inflammation/Immunology
TAK-020 is a covalent *Btk* inhibitor, which becomes the clinical candidate.

HY-128403

BTK inhibitor 8	Btk	Inflammation/Immunology
BTK inhibitor 8 (Compound 27) is a *Btk* inhibitor with an IC₅₀ of 0.11 nM. BTK inhibitor 8 inhibits Btk activity. BTK inhibitor 8 suppresses B cell activation. BTK inhibitor 8 is applicable to research related to arthritis and asthma .

HY-101766

Btk inhibitor 2	Btk	Inflammation/Immunology
Btk inhibitor 2 is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

HY-174850

CFON-026	Btk	Cancer
CFON-026 is a selective, orally active and non-covalent *BTK* inhibitor with an IC₅₀ of 0.27  nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia .

HY-130983

N-piperidine Ibrutinib hydrochloride	Btk Ligands for Target Protein for PROTAC	Cancer
N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent *BTK* inhibitor with IC₅₀s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively . N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620 (HY-133137). SJF620 is a potent PROTAC BTK degrader with a DC₅₀ of 7.9 nM .

HY-149391

PROTAC BTK Degrader-6	PROTACs Btk	Inflammation/Immunology
PROTAC BTK Degrader-6 (Compound 15) is a PROTAC *BTK* degrader (DC₅₀: 3.18 nM. PROTAC BTK Degrader-6 has anti-inflammatory activity, inhibits NF-κB activation, and inhibits the expression of pro-inflammatory cytokines (e.g. IL-1β, IL-6) .

HY-136531

XMU-MP-3	Btk Apoptosis	Cancer
XMU-MP-3 is a potent non-covalent *BTK* inhibitor with IC₅₀s of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation in the presence of 10 μM ATP, respectively. XMU-MP-3 also induces apoptosis .

HY-131328A

(R)-Pirtobrutinib (R)-LOXO-305	Btk	Others
(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations .

HY-130255

BTK inhibitor 13	Btk	Inflammation/Immunology
BTK inhibitor 13 (compound 8) is a potent and selective Bruton's tyrosine kinase (BTK) inhibitor with an IC₅₀ of 1.2 nM .

HY-145373

BMS-986143	Btk	Inflammation/Immunology
BMS-986143 is an orally active, reversible *BTK* inhibitor with an IC₅₀ of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC₅₀s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases .

HY-152212

BTK-IN-19	Btk	Inflammation/Immunology
BTK-IN-19 (Compound 51) is a reversible *BTK* inhibitor with an IC₅₀ of <0.001 μM .

HY-174129

TM471-1	Btk Apoptosis	Cancer
TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC₅₀ values of 1.3 nM (BTK ^WT), >40,000 nM (BTK ^C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis .

HY-131705

BTK inhibitor 17	Btk	Inflammation/Immunology
BTK inhibitor 17 is a potent and orally active irreversible *BTK* inhibitor with an IC₅₀ of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research .

HY-139881

BTK inhibitor 19	Btk	Cancer
BTK inhibitor 19 is a highly selective, covalent *BTK* inhibitor (IC₅₀ = 2.7 nM).

HY-125997

BTK inhibitor 10	Btk	Inflammation/Immunology
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment .

HY-170324

BTK-IN-40	Btk	Others
BTK-IN-40 (compound 375) is a *BTK* inhibitor .

HY-147580

BTK-IN-10	Btk	Cancer
BTK-IN-10 is a potent *BTK* inhibitor with IC₅₀s of <5 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022012509A1; example 111) .

HY-148832

BTK-IN-20	Btk	Inflammation/Immunology Cancer
BTK-IN-20 (compound 283) is a *BTK* tyrosine kinase inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. BTK-IN-20 can be used for the research of cancer and inflammation .

HY-162280

PROTAC BTK Degrader-9	PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk	Cancer
PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca ²⁺-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .

HY-177103

Midobrutinib	Btk	Cancer
Midobrutinib (Example 13) is a *BTK* inhibitor (IC₅₀: 0.813 nM). Midobrutinib can be used for research of diseases involving BTK, particularly cancer .

HY-168963

PROTAC BTK Degrader-13	PROTACs Btk Itk p38 MAPK	Inflammation/Immunology Cancer
PROTAC BTK Degrader-13 (Compound 25) is the PROTAC degrader for *BTK* with a DC₅₀ of 0.27 μM. PROTAC BTK Degrader-13 inhibits the activity of *BTK* with an IC₅₀ of 0.44 μM, inhibits IL-2-induced T cell kinase (ITK) with an IC₅₀ of 2.16 μM. PROTAC BTK Degrader-13 inhibits p38 MAPK signaling pathway, block the activation of the BCR (B cell receptor) signaling pathway . (Pink: ligand for target protein BTK ligand 15 (HY-168965); Black: linker (HY-Y0524); Blue: ligand for E3 ligase cereblon (HY-103596))

HY-147584

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of *BTK. BTK* plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

HY-164002

PF-303	Btk	Others
PF-303 is a potent, oral inhibitor of Bruton's tyrosine kinase (BTK) (IC₅₀=0.64 nM). The melamine portion of PF-303 forms a covalent bond with *BTK's* Cys481, which is reversible and exhibits a high selectivity compared to irreversible covalent *BTK* inhibitors. PF-303 can be used to model and study the effects of *BTK* inhibition on the mature immune system, including effects on B-cell subsets, antibody responses, and T-cell-mediated activation .

HY-151961

RSH-7	Btk FLT3	Cancer
RSH-7 is a potent *BTK* and FLT3 inhibitor with IC₅₀s of 47, 12 nM, respectively. RSH-7 induces apoptosis and shows antiproliferative activities. RSH-7 inhibits BTK and FLT3 signaling and shows anti-tumor activity .

HY-110013

Terreic acid	Btk Antibiotic	Infection Inflammation/Immunology
Terreic acid, a quinone epoxide antibiotic, acts as an effective *Btk* inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC₅₀ of approximately 100 μM .

HY-132196

BTK inhibitor 18	Btk	Inflammation/Immunology
BTK inhibitor 18 is a potent, selective,orally active and covalent *Btk* inhibitor with a IC₅₀ of 142 nM. BTK inhibitor 18 has anti-inflammatory activities .

HY-143730

BTK inhibitor 20	Btk	Cancer
BTK inhibitor 20 is a potent *BTK* inhibitor with an IC₅₀ of 8 nM .

HY-162257

BTK-IN-34	Btk	Cancer
BTK-IN-34 (compound 9h) is a selective *BTK* inhibitor. BTK-IN-34 shows antiproliferative activity in RAMOS cells through selective inhibition of pBTK (Tyr223) without affecting Lyn and Syk, upstream proteins in the BCR signaling pathway .

HY-153705

BTK-IN-25	Btk	Cancer
BTK-IN-25 (compound 71) is a potent inhibitor of *BTK, and inhibits* BTK(C481S) with an IC₅₀ value of 0.77 nM. BTK-IN-25 inhibits BTK in DOHH2 cells with an IC₅₀ value of 1 nM .

HY-162081

BTK-IN-32	Btk	Cancer
BTK-IN-32 (compound C2) is a potent inhibitor of *BTK. BTK-IN-32 activates full-length BTK* and smaller multidomain BTK fragments instead of the isolated kinase domain .

HY-150752

BTK-IN-15	Btk Pyroptosis	Cancer
BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits *BTK* with an IC₅₀ value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis .

HY-141689

BTK-IN-3	Btk	Cancer
BTK-IN-3 (example 1) is an inhibitor of *BTK. BTK*-IN-3 can used to study cancer .

HY-157159

BTK-IN-28	Btk	Cancer
BTK-IN-28 (compound PID-4) is a potent *BTK* inhibitor with anticancer activity. BTK-IN-28 has inhibitory effects on BTK and downstream signaling cascades and selectively inhibits Burkitt lymphoma RAMOS proliferation. BTK-IN-28 has no significant cytotoxicity towards non-tumor cells .

Cat. No.	Product Name

HY-L009

Kinase Inhibitor Library

3,849 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 3,849 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L009M

Kinase Inhibitor Library Mini

270 compounds

Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available.

The MCE Kinase Inhibitor Library Mini contains 270 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.

HY-L016

Protein Tyrosine Kinase Compound Library

1,578 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L129

Target Protein Ligand Library

94 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 94 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Cat. No.	Product Name	Type

HY-110002

LFM-A13 1 Publications Verification	Biochemical Assay Reagents
LFM-A13 is a potent *BTK, JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6744

Chaetoglobosin A	Infection Alkaloids Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Marine natural products Endogenous metabolite Marine microorganism Disease Research Fields Indole Alkaloids Source Classification	Apoptosis Endogenous Metabolite Fungal Parasite Arp2/3 Complex
Chaetoglobosin A is a secondary metabolite and nematicide. Chaetoglobosin A is produced by Penicillium aquamarinium. Chaetoglobosin A targets Filamentous actin in cells, thereby inducing cell cycle arrest, and inhibiting membrane ruffle formation and cell migration. Chaetoglobosin A preferentially induces Apoptosis in chronic lymphocytic leukemia cells. Chaetoglobosin A induces dose- and time-dependent death in J2 larvae of the southern root-knot nematode (Meloidogyne incognita). Chaetoglobosin A can be used in studies related to root-knot nematode disease and chronic lymphocytic leukemia .

HY-110013

Terreic acid	Microorganisms Source Classification	Btk Antibiotic
Terreic acid, a quinone epoxide antibiotic, acts as an effective *Btk* inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC₅₀ of approximately 100 μM .

Cat. No.	Product Name	Chemical Structure

HY-17600S

Acalabrutinib-d4
Acalabrutinib-d₄ (ACP-196-d₄) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor . Acalabrutinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10997S

Ibrutinib-d5
Ibrutinib-d₅ (PCI-32765-d₅) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor .

HY-101474S

Zanubrutinib-d5
Zanubrutinib-d₅ is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor .

HY-101474BS

(R)-Zanubrutinib-d5
(R)-Zanubrutinib-d₅ is deuterium labeled (R)-Zanubrutinib. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.

HY-153951S

BTK-IN-26
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for *BTK* and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-160219S

BTK-IN-33
BTK-IN-33 is a *Btk* inhibitor with anticancer effects (WO2023174300A1; compound I) .

HY-W757743

Acalabrutinib-d3
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-135334S

ACP-5862-d4

ACP-5862-d₄ is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC₅₀ of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC₅₀ of 3 nM and EC₅₀ of 8 nM .

Cat. No.	Product Name		Classification

HY-15809

(Rac)-Ibrutinib alkyne		Alkynes
(Rac)-Ibrutinib alkyne (Compound 8) is a *Btk* inhibitor with an IC₅₀ of 0.72 nM. (Rac)-Ibrutinib alkyne can effectively inhibit functions related to the B-cell receptor signaling pathway, with an IC₅₀ of 9 nM for inhibiting Ca flux in Ramos cells. (Rac)-Ibrutinib alkyne can be used in the research of diseases such as rheumatoid arthritis .

HY-159589

BTK-IN-37		Azide
BTK-IN-37 (compound 8d) is a *BTK* inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with K_i and IC₅₀ of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks